Cadrenal Therapeutics, Inc.

The momentum for this stock is not very good. Cadrenal Therapeutics, Inc. is not very popular among insiders. Tradey thinks it is not wise to invest in Cadrenal Therapeutics, Inc..

News

Cadrenal Therapeutics to discuss tecarfarin trial with FDA in September

The Fly See the rest of the story here.\n\nthefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...\n more…

Cadrenal Therapeutics Announces Upcoming Type-B FDA Meeting in September to Discuss Tecarfarin Trial in LVAD Patients

PR Newswire Cadrenal Therapeutics Announces Upcoming Type-B FDA Meeting in September to Discuss Tecarfarin Trial in LVAD Patients Cadrenal Therapeutics Announces Upcoming Type-B FDA Meeting in September to...\n more…

Cadrenal Therapeutics Inc trading resumes

Published Findings Highlight Tecarfarin's Potential and Reinforce Need for Better Anticoagulation Therapy in LVAD Patients

PR Newswire Published Findings Highlight Tecarfarin's Potential and Reinforce Need for Better Anticoagulation Therapy in LVAD Patients Published Findings Highlight Tecarfarin's Potential and Reinforce Need for...\n more…

Cadrenal Therapeutics Inc trading halted, news pending

Cadrenal Therapeutics to Present at Upcoming Investor Conferences

PR Newswire Cadrenal Therapeutics to Present at Upcoming Investor Conferences Cadrenal Therapeutics to Present at Upcoming Investor Conferences PR Newswire PONTE VEDRA, Fla., Aug. 14, 2024 PONTE VEDRA, Fla...\n more…